Table 4.
Effect of IPTp-SP doses on maternal anaemia, fetal anaemia and preterm delivery
| Outcome | Univariate analysis | Multivariable analysis | |||
|---|---|---|---|---|---|
| n (%) | cOR, 95% CI | p-value | aOR, 95% CI | p-value | |
| Maternal anemia | |||||
| 0–2 doses | 187 (47.1) | 1.23 (0.96–1.57) | 0.10 | 1.36 (1.04–1.79) | 0.02a |
| ≥ 3 doses | 321 (42.0) | Ref | Ref | Ref | Ref |
| Fetal anemia | |||||
| 0–2 doses | 36 (9.1) | 0.84 (0.56–1.27) | 0.41 | 0.85 (0.54–1.34) | 0.49b |
| ≥ 3 doses | 81 (10.6) | Ref | Ref | Ref | Ref |
| Preterm delivery | |||||
| 0–2 doses | 37 (9.3) | 1.38 (0.89–2.14) | 0.15 | 1.06 (0.65–1.73) | 0.81c |
| ≥ 3 doses | 53 (6.9) | Ref | Ref | Ref | Ref |
a Adjusted for placental malaria, ANC visits, FEFO use, peripheral malaria, mebendazole, ITN, mosquito spray/repellent and gravidity
b Adjusted for placental malaria, ANC visits, FEFO use, peripheral malaria, mebendazole, ITN, mosquito spray/repellent, maternal anaemia, sex of newborn and gravidity
c Adjusted for placental malaria, ANC visits, FEFO use, peripheral malaria, mebendazole, ITN, mosquito spray/repellent, gravidity, maternal anaemia and age of mothers